Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $2.98 Million - $3.26 Million
-7,300 Reduced 64.6%
4,000 $1.67 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $2.16 Million - $2.59 Million
6,300 Added 126.0%
11,300 $4.6 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $1.69 Million - $1.81 Million
5,000 New
5,000 $1.74 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $821,490 - $916,589
-3,000 Reduced 33.33%
6,000 $1.74 Million
Q2 2022

Aug 17, 2022

SELL
$234.96 - $292.55 $2.02 Million - $2.52 Million
-8,600 Reduced 48.86%
9,000 $2.54 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $2.79 Million - $3.29 Million
12,600 Added 252.0%
17,600 $4.59 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $885,050 - $1.12 Million
5,000 New
5,000 $1.1 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $2.72 Million - $3.04 Million
-15,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $2.01 Million - $2.37 Million
10,700 Added 248.84%
15,000 $3.02 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $2.05 Million - $2.69 Million
-9,100 Reduced 67.91%
4,300 $1.25 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $259,701 - $322,153
1,300 Added 10.74%
13,400 $3.19 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $66,684 - $89,564
-400 Reduced 3.2%
12,100 $2.65 Million
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $1.8 Million - $2.02 Million
10,800 Added 635.29%
12,500 $2.12 Million
Q2 2019

Aug 13, 2019

SELL
$164.61 - $190.37 $1.56 Million - $1.81 Million
-9,500 Reduced 84.82%
1,700 $311,000
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $1.83 Million - $2.18 Million
11,200 New
11,200 $2.06 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.